[A18-38] Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06
Last updated 02.08.2018
Commission awarded on 12.06.2018 by the Federal Joint Committee (G-BA).
Head and nerves
Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)
Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: added benefit not proven. PPMS: indication of lesser benefit than appropriate comparator therapy
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.